IO Biotech Statistics
Total Valuation
IO Biotech has a market cap or net worth of $65.88 million. The enterprise value is $46.11 million.
Important Dates
The next estimated earnings date is Tuesday, November 11, 2025, before market open.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
IO Biotech has 65.88 million shares outstanding. The number of shares has increased by 6.14% in one year.
| Current Share Class | 65.88M |
| Shares Outstanding | 65.88M |
| Shares Change (YoY) | +6.14% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.34% |
| Owned by Institutions (%) | 16.95% |
| Float | 34.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 41.38 |
| P/TBV Ratio | 41.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.96, with a Debt / Equity ratio of 5.25.
| Current Ratio | 1.96 |
| Quick Ratio | 1.47 |
| Debt / Equity | 5.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -392.10 |
Financial Efficiency
Return on equity (ROE) is -212.51% and return on invested capital (ROIC) is -114.42%.
| Return on Equity (ROE) | -212.51% |
| Return on Assets (ROA) | -80.63% |
| Return on Invested Capital (ROIC) | -114.42% |
| Return on Capital Employed (ROCE) | -442.29% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.30M |
| Employee Count | 80 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, IO Biotech has paid $918,000 in taxes.
| Income Tax | 918,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.35% in the last 52 weeks. The beta is 0.21, so IO Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | -19.35% |
| 50-Day Moving Average | 1.31 |
| 200-Day Moving Average | 1.23 |
| Relative Strength Index (RSI) | 51.58 |
| Average Volume (20 Days) | 9,487,712 |
Short Selling Information
The latest short interest is 1.14 million, so 1.73% of the outstanding shares have been sold short.
| Short Interest | 1.14M |
| Short Previous Month | 2.33M |
| Short % of Shares Out | 1.73% |
| Short % of Float | 3.29% |
| Short Ratio (days to cover) | 0.25 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -99.20M |
| Pretax Income | -103.07M |
| Net Income | -103.99M |
| EBITDA | -98.95M |
| EBIT | -99.20M |
| Earnings Per Share (EPS) | -$1.58 |
Full Income Statement Balance Sheet
The company has $28.13 million in cash and $8.36 million in debt, giving a net cash position of $19.78 million or $0.30 per share.
| Cash & Cash Equivalents | 28.13M |
| Total Debt | 8.36M |
| Net Cash | 19.78M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | 1.59M |
| Book Value Per Share | 0.02 |
| Working Capital | 19.08M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$83.33 million and capital expenditures -$75,000, giving a free cash flow of -$83.40 million.
| Operating Cash Flow | -83.33M |
| Capital Expenditures | -75,000 |
| Free Cash Flow | -83.40M |
| FCF Per Share | -$1.27 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IO Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.14% |
| Shareholder Yield | -6.14% |
| Earnings Yield | -157.84% |
| FCF Yield | -126.59% |
Analyst Forecast
The average price target for IO Biotech is $3.50, which is 250.00% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.50 |
| Price Target Difference | 250.00% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |